J&J prostate cancer drug reduces risk of cancer spread, death

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Monitor

J&J drug reduces risk of prostate cancer spread and death in late-stage study

Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ...
الشرق الأوسط

J&J Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-stage Study

Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of ...
The New England Journal of Medicine

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...